We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 26, 2021

Overall Survival Associated With Ixazomib, Lenalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
J. Clin. Oncol 2021 Jun 11;[EPub Ahead of Print], PG Richardson, SK Kumar, T Masszi, N Grzasko, NJ Bahlis, M Hansson, L Pour, I Sandhu, P Ganly, BW Baker, SR Jackson, AM Stoppa, P Gimsing, L Garderet, C Touzeau, FK Buadi, JP Laubach, M Cavo, M Darif, R Labotka, D Berg, P Moreau

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading